News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2023 Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions Michael O'Riordan March 07, 2023
News Conference News ACC 2023 PULSED AF ‘Strengthens the Case’ for Pulsed-Field Ablation in AF Todd Neale March 06, 2023
Presentation ACC 2023 Rate-Adaptive Atrial Pacing for Heart Failure with preserved Ejection Fraction: The RAPID-HF trial Presenter: Barry A. Borlaug March 06, 2023
News Conference News ACC 2023 RAPID-HF: Rate-Adaptive Pacing Doesn’t Help in HFpEF Todd Neale March 05, 2023
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Conference News ACC 2022 BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short Todd Neale April 11, 2022
News Conference News ACC 2022 Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough Michael O'Riordan April 04, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients Todd Neale May 17, 2021
News Conference News ACC 2021 Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III Todd Neale May 15, 2021
News Conference News ACC 2019 Apple Watch May Detect A-fib in the General Population, but at What Cost? Yael L. Maxwell March 16, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ACC 2018 Smartwatch Device Accurately Detects A-fib Before Cardioversion Todd Neale March 02, 2018
News Conference News ACC 2017 My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time Shelley Wood March 23, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017